Management of Early Parkinson Disease (original) (raw)

Treatment of Parkinson's disease should begin with a dopamine agonist

Olivier Rascol

Movement Disorders, 2000

View PDFchevron_right

Treatment options for the management of parkinsonism

colette davidson

Prescriber, 2009

View PDFchevron_right

How to optimize the treatment of early stage Parkinson’s disease

F. Stocchi

Translational Neurodegeneration, 2015

View PDFchevron_right

Management of Parkinson’s disease

Peter Silburn

Australian Prescriber, 2012

View PDFchevron_right

Treatment of early Parkinson's disease

Olivier Rascol

European …, 2009

View PDFchevron_right

Drug management of Parkinson's disease

Asha Kishore

View PDFchevron_right

Pharmacotherapy for Parkinson's disease

Jack Chen

Pharmacotherapy, 2007

View PDFchevron_right

An update on the management of young-onset Parkinson's disease

Ivo Lušić

Degenerative Neurological and Neuromuscular Disease, 2013

View PDFchevron_right

Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study

M. Musicco

Parkinsonism & Related Disorders, 2001

View PDFchevron_right

Current Pharmacotherapeutic Treatment Options in Parkinson’s Disease

Michael Rezak

Disease-a-Month, 2007

View PDFchevron_right

An update on the management of young-onset Parkinson's disease

Eduard Margetic

Degenerative Neurological and Neuromuscular Disease, 2013

View PDFchevron_right

Initial treatment of early Parkinson’s disease: A review of recent, randomized controlled trials

Kevin Biglan

Current Neurology and Neuroscience Reports, 2001

View PDFchevron_right

Diagnosis and Pharmacological Management of Parkinson's Disease: A Review

International Journal of Health Sciences and Research (IJHSR)

https://www.ijhsr.org/IJHSR\_Vol.12\_Issue.2\_Feb2022/IJHSR-Abstract.015.html, 2022

View PDFchevron_right

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

Emma McIntosh

Lancet, 2014

View PDFchevron_right

Recommendations for the Treatment of Parkinson's Disease

Craig Stern

Journal of Contemporary Pharmacy Practice, 2018

View PDFchevron_right

Early treatment of Parkinson's disease: opportunities for managed care

Daniel Murman

The American journal of managed care, 2012

View PDFchevron_right

Treatment of Parkinson's Disease

abraham lieberman

Mayo Clinic Proceedings, 1988

View PDFchevron_right

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review

Edna Schechtman

Neurology

View PDFchevron_right

Parkinson Disease Treatment

Daniel Martinez-Ramirez

View PDFchevron_right

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society?European Section. Part I: early (uncomplicated) Parkinson's disease

Cristina Sampaio

European Journal of Neurology, 2006

View PDFchevron_right

The Challenge of Managing Mild Parkinson's Disease

Peter Lewitt

Pharmacotherapy, 2000

View PDFchevron_right

Treatment strategies in advanced Parkinson's disease: Review of the literature

Yıldız Değirmenci

Cumhuriyet Medical Journal, 2017

View PDFchevron_right

Treating the Motor Symptoms of Parkinson Disease

Alexandre Pulido

View PDFchevron_right

Should dopamine agonists be given early or late in the treatment of Parkinson's disease?

Olivier Rascol

View PDFchevron_right

Early (Uncomplicated) Parkinson's Disease

Cristina Sampaio

European Handbook of Neurological Management: Second Edition, 2010

View PDFchevron_right

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy

Lakshmi Sekaran

JAMA Neurology

View PDFchevron_right

Pharmacological Management of Parkinson's Disease

Robert Iansek

Journal of Pharmacy Practice and Research, 2004

View PDFchevron_right

Levodopa in the treatment of Parkinson's disease: Current controversies

Peter Lewitt

Movement Disorders, 2005

View PDFchevron_right

Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease

Richard Dewey

Progress in medicinal chemistry, 1984

View PDFchevron_right

DOPA-sparing strategy in the treatment of young onset Parkinson's disease

Syed Fasih Ullah Hussaini

Journal of Neurosciences in Rural Practice, 2016

View PDFchevron_right

Parkinson’s disease: will therapy move beyond dopaminergic medication?

László Vecsei

Clinical Investigation, 2011

View PDFchevron_right

Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology

Edna Schechtman

Neurology, 2002

View PDFchevron_right

The key points for treatment of Parkinsonism in older persons

Andrea Ticinesi

Geriatric Care, 2017

View PDFchevron_right

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease

Olivier Rascol

European Journal of Neurology, 2006

View PDFchevron_right